Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Colebatch

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
JAMA Surgery|February 9, 2022
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III MelanomaIrene L M Reijers, Robert V Rawson, Andrew J Colebatch, et al.
JCO Precision Oncology|February 17, 2022
Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic MelanomaStephen Q Wong, Jeanette M Raleigh, Jason Callahan, et al.
Cancer Research|December 3, 2015
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell CarcinomasStephen Q Wong, Kelly Waldeck, Ismael A Vergara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology GroupMichael R Sargen, Raymond L Barnhill, David E Elder, et al.
Cancer Discovery|September 13, 2022
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma SubtypesFelicity Newell, Peter A Johansson, James S Wilmott, et al.
Nature Medicine|June 6, 2022
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trialIrene L M Reijers, Alexander M Menzies, Alexander C J van Akkooi, et al.
Pathology|December 23, 2021
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian settingRichard A Scolyer, Victoria Atkinson, David E Gyorki, et al.
Nature Medicine|January 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trialLotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
JAMA Surgery|February 9, 2022
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III MelanomaIrene L M Reijers, Robert V Rawson, Andrew J Colebatch, et al.
JCO Precision Oncology|February 17, 2022
Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic MelanomaStephen Q Wong, Jeanette M Raleigh, Jason Callahan, et al.
Cancer Research|December 3, 2015
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell CarcinomasStephen Q Wong, Kelly Waldeck, Ismael A Vergara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology GroupMichael R Sargen, Raymond L Barnhill, David E Elder, et al.
Cancer Discovery|September 13, 2022
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma SubtypesFelicity Newell, Peter A Johansson, James S Wilmott, et al.
Nature Medicine|June 6, 2022
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trialIrene L M Reijers, Alexander M Menzies, Alexander C J van Akkooi, et al.
Pathology|December 23, 2021
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian settingRichard A Scolyer, Victoria Atkinson, David E Gyorki, et al.
Nature Medicine|January 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trialLotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, et al.
Pageof 6